"Drug Costs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).
| Descriptor ID |
D016527
|
| MeSH Number(s) |
N03.219.151.400.350 N05.300.375.300
|
| Concept/Terms |
Drug Costs- Drug Costs
- Cost, Drug
- Costs, Drug
- Drug Cost
|
Below are MeSH descriptors whose meaning is more general than "Drug Costs".
Below are MeSH descriptors whose meaning is more specific than "Drug Costs".
This graph shows the total number of publications written about "Drug Costs" by people in this website by year, and whether "Drug Costs" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 3 | 4 |
| 2002 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 1 | 3 | 4 |
| 2006 | 0 | 4 | 4 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 4 | 5 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 3 | 4 |
| 2011 | 1 | 3 | 4 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 2 | 2 | 4 |
| 2016 | 1 | 4 | 5 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 4 | 5 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 4 | 5 |
| 2021 | 5 | 2 | 7 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Costs" by people in Profiles.
-
Valikodath NG, Rathinavelu J, Deaner JD, Buckley M, Grewal DS. Comparison of Reference and Biosimilar Medications for Pediatric Noninfectious Uveitis. Int Ophthalmol Clin. 2024 Oct 01; 64(4):69-73.
-
Neumann S, Alverson B. Nirsevimab: The Hidden Costs. Hosp Pediatr. 2024 05 09; 14(6).
-
Lauriello J, Weiden PJ, Gleeson CD, Shah A, Boulanger L, Jariwala-Parikh K, Hedgeman E, O'Sullivan AK. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia. CNS Drugs. 2021 10; 35(10):1123-1135.
-
Al-Khersan H, Fowler BJ, Clauss KD, Kunkler AL, Yannuzzi NA, Patel NA, Sridhar J, Albini TA, Smiddy WE. Cost-Utility Analysis of Mycophenolate Mofetil versus Methotrexate for Noninfectious Uveitis. Ophthalmol Retina. 2021 12; 5(12):1281-1282.
-
Wong ND, Bang M, Block RC, Peterson ALH, Karalis DG. Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists). Am J Cardiol. 2021 08 01; 152:57-62.
-
Choi S, Chen EM, Chen D, Sridhar J, Parikh R. The Impact of International Pricing Index Models on Anti-Vascular Endothelial Growth Factor (VEGF) Drug Costs in the United States. Semin Ophthalmol. 2022 Jan 02; 37(1):23-28.
-
Watane A, Kalavar M, Reyes J, Yannuzzi NA, Sridhar J. The Effect of Market Competition on the Price of Topical Eye Drops. Semin Ophthalmol. 2022 Jan 02; 37(1):42-48.
-
Barbarite E, Occhiogrosso J, McCarty JC, Lee LN, Hadlock TA, Shaye DA, Gadkaree SK. Opioid Prescribing Patterns Among Facial Plastic and Reconstructive Surgeons in the Medicare Population. Facial Plast Surg Aesthet Med. 2021 12; 23(6):401-404.
-
Khanal O, Lenhoff AM. Developments and opportunities in continuous biopharmaceutical manufacturing. MAbs. 2021 Jan-Dec; 13(1):1903664.
-
Bluher AE, Moody-Antonio S. Rising Costs of Otic Drops: Review of a National Database. Laryngoscope. 2021 04; 131(4):E1069-E1075.